Loading...
•
Sep 30, 2024
Tourmaline Bio Q3 2024 Earnings Report
Reported financial results for the third quarter of 2024 and outlined recent business highlights.
Key Takeaways
Tourmaline Bio reported a net loss of $20.2 million for the third quarter of 2024. Cash, cash equivalents and investments were $314.4 million as of September 30, 2024, providing cash runway into 2027.
On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025.
Assembled Cardiovascular Scientific Advisory Board (CV SAB) in October 2024.
Showcased poster presentations at the American Society of Preventive Cardiology Annual Congress in August 2024 and the 19th Annual Cardiometabolic Health Congress in October 2024.
Cash, cash equivalents and investments of $314.4 million as of September 30, 2024, providing cash runway into 2027.
Forward Guidance
Tourmaline anticipates that its current cash, cash equivalents and investments will provide cash runway into 2027, funding its operations through key pacibekitug data readouts in TED and cardiovascular disease and providing the opportunity to expand development efforts into additional indications.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...